血清胱抑素C (CysC)是一种细胞外抑制素,在体液中丰富的表达,可能对间质半胱氨酸蛋白酶有抑制作用。分子量较小,产生率恒定,可以调控细胞内外的蛋白水解,并且可经肾小球过滤,在近曲小管重吸收和代谢,肾脏是将其清除的唯一器官,同时,它不受性别、年龄、饮食等因素影响。血清胱抑素C (CysC)测定是测定肾脏病患者肾功能的一种简单实用的方法。最近的研究表明,CysC在预测肾损害的早期阶段具有更好的诊断准确性或至少相当于肌酐,并且与透析患者的临床结果密切相关。因此,胱抑素C在肾脏疾病、肿瘤、糖尿病、肝硬化、心脏病的诊断中有一定价值,本文对血清胱抑素C在肾脏病诊断中的价值作一论述。
Serum cystatin C (CysC) is a kind of extracellular inhibin, which is abundant in body fluid and may inhibit interstitial cysteine protease. The molecular weight is small, the production rate is constant, it can regulate the protein hydrolysis inside and outside the cell, and it can be filtered by the glomerulus and reabsorbed and metabolized in the proximal convoluted tubule. The kidney is the only organ to remove it, and at the same time, it is not affected by sex, age, diet and other factors. The determination of serum cystatin C (CysC) is a simple and practical method to measure the renal function of patients with renal disease. Recent studies have shown that CysC is more accurate or at least equivalent to creatinine in predicting the early stage of renal damage and is closely related to the clinical outcome of dialysis patients. Therefore, cystatin C has certain value in the diagnosis of kidney disease, tumor, diabetes, liver cirrhosis and heart disease. This paper discusses the value of serum cystatin C in the diagnosis of kidney disease.
血清胱抑素C,肾功能损害,肾脏病诊断, Serum Cystatin C Renal Damage Diagnosis of Kidney Disease血清胱抑素C对肾脏病诊断的价值
葛栋栋,刘金彦. 血清胱抑素C对肾脏病诊断的价值The Value of Serum Cystatin C in the Diagnosis of Renal Diseases[J]. 临床医学进展, 2020, 10(08): 1689-1693. https://doi.org/10.12677/ACM.2020.108253
参考文献ReferencesZi, M. and Xu, Y. (2018) Involvement of Cystatin C in Immunity and Apoptosis. Immunology Letters, 196, 80-90.
<br>https://doi.org/10.1016/j.imlet.2018.01.006Kar, S., Paglialunga, S. and Islam, R. (2018) Cystatin C Is a More Reliable Biomarker for Determining eGFR to Support Drug Development Studies. Journal of Clinical Pharmacology, 58, 1239-1247. <br>https://doi.org/10.1002/jcph.1132刘宁, 成金钟, 陈亚巍. 测定慢性肾小球肾炎患者血清胱抑素C水平的变化及意义[J]. 中华保健医学杂志, 2012, 14(2): 150-152.赵帆, 张枚, 何訸, 等. 糖尿病肾病患者血清胱抑素C和尿微量白蛋白检测水平分析[J]. 中国实验诊断学, 2018, 22(10): 1711-1714.Satirapoj, B. (2018) Tubulointerstitial Biomarkers for Diabetic Nephropathy. Journal of Diabetes Research, 2018, Article ID: 2852398. <br>https://doi.org/10.1155/2018/2852398Elsayed, M.S., El Badawy, A., Ahmed, A., et al. (2019) Serum Cystatin C as an Indicator for Early Detection of Diabetic Nephropathy in Type 2 Diabetes Mellitus. Diabetes & Metabolic Syndrome, 13, 374-381.
<br>https://doi.org/10.1016/j.dsx.2018.08.017杨建宝, 李金巍. 高血压肾病患者的中性粒细胞明胶酶相关脂质运载蛋白、胱抑素C、肌酐、尿素氮水平及其临床意义研究[J]. 中国临床医生杂志, 2018, 46(4): 408-410.蒋琰, 刘如石, 李原, 等. 血清胱抑素C、同型半胱氨酸联合检测对诊断高血压早期肾病的意义[J]. 重庆医学, 2015, 44(9): 1193-1196.Bhavsar, N.A., Appel, L.J., Kusek, J.W., et al. (2011) Comparison of Measured GFR, Serum Creatinine, Cystatin C, and Beta-Trace Protein to Predict ESRD in African Americans with Hypertensive CKD. American Journal of Kidney Diseases, 58, 886-893. <br>https://doi.org/10.1053/j.ajkd.2011.07.018Naito, Y., Sawada, H., Oboshi, M., et al. (2013) Increased Renal Iron Accumulation in Hypertensive Nephropathy of Salt-Loaded Hypertensive Rats. PLoS ONE, 8, e75906. <br>https://doi.org/10.1371/journal.pone.0075906Tylicki, L. and Rutkowski, B. (2003) Hypertensive Nephropathy: Pathogenesis, Diagnosis and Treatment. Polski merkuriusz lekarski: Organ Polskiego Towarzystwa Lekarskiego, 14, 168-173.Wali, U., Hussain, M.M., Wali, N., et al. (2019) Comparison of Serum Levels of Cystatin-C and Traditional Renal Biomarkers for the Early Detection of Pre-Hypertensive Nephropathy. Journal of Pakistan Medical Association, 69, 313-319.武敏, 黄传兵, 贾建云, 等. 胱抑素C在系统性红斑狼疮肾损害中的研究概况[J]. 中医药临床杂志, 2015, 27(1): 17-20.赵秀芬, 黄智敏, 钱军, 等. 血清胱抑素C与IgA肾病Lee氏病理分级的相关性[J]. 江苏医药, 2016, 42(23): 2553-2555.向莉, 周华, 李旻, 等. 胱抑素C评估IgA肾病患者肾纤维化程度及早期肾损害的价值[J]. 江苏医药, 2012, 38(16): 1899-1901.Peixoto, L., Aguiar, P., de Braganca, R., et al. (2015) Cystatin C: A Promising Marker of Renal Function in Patients with Systemic Lupus Erythematosus? Acta Médica Portuguesa, 28, 333-341. <br>https://doi.org/10.20344/amp.5770Kokkoris, S., Pipili, C., Grapsa, E., et al. (2013) Novel Biomarkers of Acute Kidney Injury in the General Adult ICU: A Review. Renal Failure, 35, 579-591. <br>https://doi.org/10.3109/0886022X.2013.773835Fouad, M. and Boraie, M. (2013) Cystatin C as an Early Marker of Acute Kidney Injury and Predictor of Mortality in the Intensive Care Unit after Acute Myocardial Infarction. Arab Journal of Nephrology and Transplantation, 6, 21-26.Leem, A.Y., Park, M.S., Park, B.H., et al. (2017) Value of Serum Cystatin C Measurement in the Diagnosis of Sepsis-Induced Kidney Injury and Prediction of Renal Function Recovery. Yonsei Medical Journal, 58, 604-612.
<br>https://doi.org/10.3349/ymj.2017.58.3.604Beker, B.M., Corleto, M.G., Fieiras, C., et al. (2018) Novel Acute Kidney Injury Biomarkers: Their Characteristics, Utility and Concerns. International Urology and Nephrology, 50, 705-713. <br>https://doi.org/10.1007/s11255-017-1781-x